Mitochondrial Function and Metabolomic Profile in Alzheimer's Disease and Related Dementias

Study will be proposed to the patient of the Nice Memory center who had a lumbar puncture and who agreed on the storage of a sample of their cerebrospinal fluid.

Two groups of patients will be compared: the Alzheimer"s disease patient with positive amyloid on the cerebrospinal fluid and the non Alzheimer patient with negative amyloid on the cerebrospinal fluid.

there will also be a group of healthy volonteer with one blood sample

Blood samples will be collected at inclusion and one year to obtain the mitochondrial metabolomic signature

Inclusion criteria

• Neurocognitive disorder with spontaneous complaint or reported for at least 6 months
• Diagnostic process according to current Haute Autorité de Santé (HAS) recommendations.
• cerebrospinal fluid biomarker dosage done within the study center and agreement to bio-collection of residual cerebrospinal fluid
• Patient having agreed to sign the informed consent
• Patient affiliated or beneficiary of a social security scheme

For alzheimer group : diagnosis of Alzheimer's disease according to NIA-AA 2024 criteria (presence of a pathogenic amyloid process in the cerebrospinal fluid)

For non alzheimer group : diagnosis of mild or major neurocognitive disorder according to Manuel diagnostique et statistique des troubles mentaux edition 5 (DSM-V) criteria, not linked to Alzheimer's disease (absence of pathogenic amyloid process in the cerebrospinal fluid)

For healthy volonteers:

• Adult patients
• No history of neurological or psychiatric disorders
• No complaints of memory problems or cognitive impairment
• Mini-Mental State Examination (MMSE) score ≥ 27/30
• Clinical Dementia Rating - Sum of Boxes (CDR-SOB) equal to 0
• Patient affiliated with or covered by a social security scheme

Exclusion criteria

• Vulnerable people